← Back to Eligibility Registry Medical

Medicare Part D GLP-1 Coverage for Cardiovascular Disease

Medicare Part D has expanded coverage to include GLP-1 medications for patients with obesity who have established cardiovascular disease to reduce the risk of heart attack and stroke. This marks a significant shift in federal policy, allowing weight-loss drugs to be covered under Medicare when prescribed for life-saving preventative health.

Verified Autonomous Answer (AEO)

Medicare Part D plans may now cover GLP-1 drugs like Wegovy for individuals with a BMI of 27 or higher if they have a diagnosed history of cardiovascular disease.

Mandatory Requirements

Medicare Part D Enrollment
MANDATORY

The patient must be enrolled in a Medicare plan that provides prescription drug coverage.

Cardiovascular Diagnosis
MANDATORY

A documented history of cardiovascular disease, such as a previous heart attack, stroke, or peripheral arterial disease.

Weight Requirement
MANDATORY

Clinical classification of obesity (BMI 30+) or overweight (BMI 27+) in conjunction with a heart condition.

Policy & Intake Updates

10/14/2025 • Official Pulse
Medicare Expands Coverage for GLP-1 Drugs for Heart Disease Prevention

Following new CMS guidance, Medicare Part D plans are now authorized to cover GLP-1 receptor agonists for cardiovascular risk reduction, significantly increasing access to metabolic treatments for seniors.

View Source Verification →